Brenda Mann Insider Trading $EYEG EYEGATE PHARMACEUTICALS INC
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Brenda Mann.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Brenda Mann. Brenda Mann is VP of Research & Development in EYEGATE PHARMACEUTICALS INC ($EYEG).
Brenda Mann in EYEGATE PHARMACEUTICALS INC
Trading Symbol: EYEGIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Brenda Mann: VP of Research & Development
Holdings: 15,693 shares
Current Value: $24,795
Latest Transaction: May 05 2021
$EYEG Market Capitalization: $15.24M
$EYEG Previous Close: $1.58
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Brenda Mann in EYEGATE PHARMACEUTICALS INC
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 05 2021 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 4.13 | 191 | 789 | 15,693 | 15.9 K to 15.7 K (-1.20 %) |
Apr 09 2021 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 4.94 | 192 | 948 | 15,884 | 16.1 K to 15.9 K (-1.19 %) |
Mar 05 2021 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 5.46 | 192 | 1,048 | 16,076 | 16.3 K to 16.1 K (-1.18 %) |
Feb 03 2021 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 6.46 | 10,000 | 64,600 | 10,000 | |
Feb 03 2021 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 6.34 | 988 | 6,264 | 16,268 | 17.3 K to 16.3 K (-5.73 %) |
Dec 08 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 3.76 | 91 | 342 | 17,371 | 17.5 K to 17.4 K (-0.52 %) |
Nov 03 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 3.51 | 96 | 337 | 17,462 | 17.6 K to 17.5 K (-0.55 %) |
Oct 05 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 3.88 | 98 | 380 | 17,558 | 17.7 K to 17.6 K (-0.56 %) |
Sep 03 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 3.94 | 97 | 382 | 17,656 | 17.8 K to 17.7 K (-0.55 %) |
Aug 05 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 4.11 | 92 | 378 | 17,753 | 17.8 K to 17.8 K (-0.52 %) |
Jul 06 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 4.82 | 94 | 453 | 17,845 | 17.9 K to 17.8 K (-0.52 %) |
Jun 04 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 5.11 | 94 | 480 | 17,939 | 18 K to 17.9 K (-0.52 %) |
May 06 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 5.10 | 113 | 576 | 18,033 | 18.1 K to 18 K (-0.62 %) |
Apr 03 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 4.97 | 122 | 606 | 18,146 | 18.3 K to 18.1 K (-0.67 %) |
Mar 10 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 5.00 | 130 | 650 | 18,268 | 18.4 K to 18.3 K (-0.71 %) |
Feb 05 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 6.00 | 109 | 654 | 10,898 | 11 K to 10.9 K (-0.99 %) |
Jan 06 2020 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 9.52 | 119 | 1,133 | 11,007 | 11.1 K to 11 K (-1.07 %) |
Dec 20 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 7.46 | 101 | 753 | 11,126 | 11.2 K to 11.1 K (-0.90 %) |
Nov 07 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 3.85 | 107 | 412 | 11,227 | 11.3 K to 11.2 K (-0.94 %) |
Oct 11 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 3.12 | 184 | 574 | 11,334 | 11.5 K to 11.3 K (-1.60 %) |
Aug 07 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Payment of Exercise | F | 0.21 | 1,641 | 345 | 172,783 | 174.4 K to 172.8 K (-0.94 %) |
Jul 15 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Sell | S | 0.23 | 6,350 | 1,480 | 174,424 | 180.8 K to 174.4 K (-3.51 %) |
Jul 15 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Sell | S | 0.24 | 6,350 | 1,496 | 180,774 | 187.1 K to 180.8 K (-3.39 %) |
Jul 15 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Sell | S | 0.24 | 6,349 | 1,528 | 187,124 | 193.5 K to 187.1 K (-3.28 %) |
Jul 15 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Sell | S | 0.23 | 6,350 | 1,480 | 174,424 | 180.8 K to 174.4 K (-3.51 %) |
Jul 15 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Sell | S | 0.24 | 6,350 | 1,496 | 180,774 | 187.1 K to 180.8 K (-3.39 %) |
Jul 15 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Sell | S | 0.24 | 6,349 | 1,528 | 187,124 | 193.5 K to 187.1 K (-3.28 %) |
Feb 05 2019 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 0.48 | 50,000 | 24,000 | 50,000 | |
Jul 12 2018 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Grant | A | 0.00 | 175,000 | 0 | 193,473 | 18.5 K to 193.5 K (+947.33 %) |
Mar 01 2018 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 0.57 | 15,000 | 8,550 | 15,000 | |
Jan 03 2018 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Buy | J | 1.01 | 6,722 | 6,789 | 18,473 | 11.8 K to 18.5 K (+57.20 %) |
Jun 22 2017 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 1.35 | 15,000 | 20,250 | 15,000 | |
Jul 19 2016 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 2.42 | 1,133 | 2,742 | 1,133 | |
Mar 31 2016 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 3.06 | 851 | 2,604 | 851 | |
Mar 09 2016 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Option Exercise | A | 3.80 | 9,500 | 36,100 | 9,500 | |
Mar 09 2016 | EYEG | EYEGATE PHARMACEUT ... | Mann Brenda | VP of Research & De ... | Buy | J | 0.00 | 9,251 | 0 | 9,251 | 0 to 9.3 K |
Page: 1